Immunological and clinical consequences of Tysabri

A board to discuss the newly-released drug Tysabri, (formerly known as Antegren) as a treatment for Multiple Sclerosis

Immunological and clinical consequences of Tysabri

Postby MSUK » Tue Sep 20, 2011 12:58 am

Immunological and clinical consequences of treating a patient with natalizumab



Background: Long-term therapy with natalizumab increases the risk of progressive multifocal leukoencephalopathy (PML).

Objectives: We present a patient study through therapy, the diagnosis of PML (after 29 infusions), plasma exchange (PE) and development of immune reconstitution inflammatory syndrome (IRIS).... Read More - ... ageid/1768
User avatar
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 3:00 pm


Re: Immunological and clinical consequences of Tysabri

Postby NHE » Tue Sep 20, 2011 2:54 am

Additional info from the abstract...
With no clinical, routine laboratory or cerebrospinal fluid (CSF) changes, MRI 2 months after PE demonstrated progressive lesion development. Brain histopathology confirmed the presence of infiltrates indicative of IRIS without clinical signs, immunologically accompanied by CCR7/CCR5 recovery of peripheral monocytes.

Conclusion: Natalizumab-associated immunological changes accompanying PML were reversible after PE; IRIS can occur very late, remain asymptomatic and be elusive to CSF analysis.

User avatar
Volunteer Moderator
Posts: 4921
Joined: Sat Nov 20, 2004 4:00 pm

Return to Tysabri (Antegren or Natalizumab)


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service